Business UpdateNov 5, 2026, 04:28 PM
Aquestive Therapeutics Furnishes Investor Presentation on Anaphylm and AQST-108
AI Summary
Aquestive Therapeutics, Inc. has filed an 8-K to furnish an investor presentation. The presentation details the company's lead asset, Anaphylm (dibutepinephrine) sublingual film, which has a PDUFA goal date of March 16, 2027, and is positioned as a novel alternative to existing epinephrine auto-injectors. It also covers AQST-108, a topical epinephrine gel for atopic dermatitis. The company reported $90.3 million in cash as of September 30, 2026, with potential access to additional funding contingent on Anaphylm's FDA approval.
Key Highlights
- Aquestive Therapeutics is furnishing an investor presentation to be given at meetings with institutional investors and analysts.
- The presentation includes information on Anaphylm (dibutepinephrine) sublingual film, with a PDUFA goal date of March 16, 2027.
- Anaphylm is positioned as a novel, needle-free, orally delivered epinephrine product for anaphylaxis.
- AQST-108 (epinephrine) topical gel is being developed for atopic dermatitis and other dermatology indications.
- The company reported $90.3 million in cash and cash equivalents as of September 30, 2026.
- Potential access to $75 million under a strategic funding agreement and $20 million from a debt facility are subject to conditions, including FDA approval of Anaphylm.
Price Impact
More from AQST